Cardiology overview pharmacology: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 25: Line 25:
* [[Pioglitazone]] is associated with an increase in weight and [[peripheral edema]]. There actually does not appear to be an increased risk of [[heart failure]] but an increased vascular permeability.  In patients with edema they should be switched to [[metformin]].
* [[Pioglitazone]] is associated with an increase in weight and [[peripheral edema]]. There actually does not appear to be an increased risk of [[heart failure]] but an increased vascular permeability.  In patients with edema they should be switched to [[metformin]].
* [[Nesiritide]] can lead to hypertension lasting for a couple of hours.
* [[Nesiritide]] can lead to hypertension lasting for a couple of hours.
* Genotyping can be used to dose warfarin in such a manner to reduce hospitalization.


==References==
==References==

Revision as of 18:08, 31 October 2011

Cardiology Overview

Home

Acute Coronary Syndromes

Antiplatelets and antithrombins

Cardiomyopathy

Congenital heart disease

Electrophysiology

Heart failure

Hypertension

Imaging

Invasive cardiology

Pericardial disease

Peripheral arterial disease

Pharmacology

Pregnancy

Preoperative evaluation

Prevention

Pulmonary hypertension

Stable angina

Valvular heart disease

Venous thromboembolism

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Drug Drug Interactions

Drug Food Interactions

Grapefruit

Drug Side Effects and Toxicity

References

Template:WS Template:WH